JPRN-UMIN000011510已完成未知
Association of the use of vitamin D receptor activators with incident cardiovascular disease and death after it in hemodialysis patients - Association of the use of vitamin D receptor activators with incident cardiovascular disease and death after it in hemodialysis patients
Japanese Society for Dialysis Therapy, Committee of Renal Data Registry (JSTD-CRDR)0 个研究点目标入组 49,659 人开始时间: 2013年10月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 49,659
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The subjects are excluded if any of the following data is unavailable; 1) the use/nonuse of VDRAs, age, sex, dialysis vintage, underlying kidney disease (diabetic or not), serum calcium, phosphate, intact PTH, albumin, CRP and body mass index at the end of 2004. 2) Information of past history of myocardial infarction, cerebral infarction or cerebral bleeding, and vital state (if dead, the cause of death) at the end of 2005.
研究者
相似试验
尚未招募
不适用
Assesment of association between Vitamin D receptor activator and circadian rhythm of blood presure; A observational cohort studyChronic kidney diseaseJPRN-UMIN000012673Kidney Disease Center, Japanese Red Cross Nagoya Daini Hospital250
招募中
不适用
Efficacy of calcitriol therapy in CKD, based on Vitamin D receptor gene polymorphismsCTRI/2020/07/026536Indian Council of Medical Research ICMR
招募中
1 期
The effect of preoperative and postoperative vitamin D medication therapy on postoperative urinary IL18,KIM1levels in modarres hospital CABG patients in 1397 yearIRCT20180131038578N1Shahid Beheshti University of Medical Sciences66
进行中（未招募）
不适用
VITAL Study-Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin Sytem Inhibitors - Not availableType 2 diabetic nephropathyMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseEUCTR2006-001363-31-DEAbbott GmbH & Co KG258
进行中（未招募）
不适用
VITAL Study-Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin Sytem Inhibitors - Not availableEUCTR2006-001363-31-PTAbbott GmbH & Co KG258